Dabigatran Etexilate Mesylate

Adults: Reduction in the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation: for patients with CrCl above 30 mL/min, the dose of Dabigatran Etexilate Mesylate is 150 mg orally, twice daily. For patients with CrCl 15 to 30 mL/min, it is 75 mg orally, twice daily. Treatment of DVT and PE: for patients with CrCl above 30 mL/min, give 150 mg orally, twice daily, after 5 to 10 days of parenteral anticoagulation. Reduction in the risk of recurrence of DVT and PE: for patients with CrCl above 30 mL/min, give 150 mg orally, twice daily, after the previous treatment. Prophylaxis of DVT and PE following hip replacement surgery: for patients with CrCl above 30 mL/min, give 110 mg orally on the first day, then 220 mg once daily. When possible, stop Dabigatran Etexilate Mesylate temporarily before invasive or surgical procedures, and restart it promptly afterwards. Pediatric use: the safety and effectiveness of Dabigatran Etexilate in pediatric patients have not been established. Geriatric use: in the RE-LY study, 82% of the patients were 65 and over, and 40% were 75 and over. The risk of stroke and bleeding rises with age, but the risk-benefit profile is favorable in all age groups.